2,4-dinitrobenzenesulfonic acid has been researched along with transforming growth factor beta in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Felley, C; Michetti, P | 1 |
| Brun, P; Castagliuolo, I; Palò, G; Tormen, D | 1 |
| Fernando, MR; Graepel, R; Leung, G; McKay, DM; Reyes, JL; Sigvardsson, M; van Rooijen, N; Wang, A | 1 |
3 other study(ies) available for 2,4-dinitrobenzenesulfonic acid and transforming growth factor beta
| Article | Year |
|---|---|
Engineered lymphocytes to treat dinitrobenzene sulphonic acid colitis in mice.
Topics: Animals; Benzenesulfonates; Colitis; Genetic Therapy; Lymphocyte Transfusion; Lymphocytes; Mice; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2003 |
Lymphocytes endowed with colon-selective homing and engineered to produce TGF-beta1 prevent the development of dinitrobenzene sulphonic acid colitis.
Topics: Animals; Antibodies, Monoclonal; Benzenesulfonates; Colitis; Cytokines; Gene Targeting; Genetic Therapy; Integrins; Lymphocyte Transfusion; Lymphocytes; Male; Mice; Mice, Inbred BALB C; Mucous Membrane; Spleen; Transfection; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2003 |
Splenic B cells from Hymenolepis diminuta-infected mice ameliorate colitis independent of T cells and via cooperation with macrophages.
Topics: Animals; Antigens, CD19; Antigens, CD1d; B-Lymphocytes; Benzenesulfonates; CD40 Antigens; CD5 Antigens; Colitis; Dextran Sulfate; Homeodomain Proteins; Hymenolepiasis; Hymenolepis diminuta; Immunomodulation; Immunotherapy; Interleukin-10; Interleukin-4; Lipopolysaccharides; Macrophages; Male; Mast Cells; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Oxazolone; Receptors, IgE; Th1 Cells; Th2 Cells; Transforming Growth Factor beta | 2015 |